Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GEN1106 |
| Synonyms | |
| Therapy Description |
GEN1106 (PRO1106) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting SLITRK6 linked with sesutecan, which potentially inhibits growth of SLITRK6-expressing tumor cells (Cancer Res (2024) 84 (6_Supplement): 2050). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GEN1106 | GEN-1106|GEN 1106|PRO-1106|PRO 1106 | GEN1106 (PRO1106) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting SLITRK6 linked with sesutecan, which potentially inhibits growth of SLITRK6-expressing tumor cells (Cancer Res (2024) 84 (6_Supplement): 2050). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07416123 | Phase I | GEN1106 | A Study of GEN1106 in Participants With Solid Tumors | Recruiting | USA | 0 |